Elevating Quality and Flexibility to Support Your ATMP Development

Plasmid DNA fulfils multiple roles in advanced therapy medicinal products (ATMPs). While it can be used directly as a drug product in applications such as DNA vaccines, the continued clinical success and widespread adoption of viral vector-based delivery have resulted in plasmids being commonly used as critical starting materials (CSM), supporting the onward manufacture of a range of different advanced therapy drug products. In this foundational role, plasmids are still incorporated structurally into final drug products and can directly determine quality attributes and functionality, making robust quality controls essential.

This whitepaper imparts advice honed by over 20 years of plasmid DNA manufacturing experience and >95% successfully released batches. Access today and enhance your ATMP manufacturing strategy.

Explore:

  • The eXpDNA™ plasmid DNA manufacturing platform
  • Flexible scales and off-the-shelf solutions
  • Linearization for mRNA manufacture
  • Quality Control (QC) for critical starting materials